Conference Coverage

Breast Cancer Risk Assessment and Chemoprevention Use Among VA Primary Care

Abstract 11: 2017 AVAHO Meeting


 

Background: Despite recommended guidelines and available medications to reduce breast cancer risk by up to 50-65%, < 5% of the 10 million eligible women are offered chemoprevention in the U.S. The comfort level, practice patterns, and barriers to breast cancer risk assessment and chemoprevention use within the VA have not been reported.

Methods: We assessed VA primary care providers using a REDcap survey. We obtained provider demographics, use and comfort level with breast cancer risk models and chemoprevention, and knowledge about chemoprevention. Data was analyzed with Fisher exact or chi-square tests.

Results: Of the 200 survey respondents, 167 were included for analysis. Overall, 30% used the Gail model monthly or more often, and 1.5% prescribed chemoprevention in the past 2 years. Fewer than 30% correctly answered chemoprevention knowledge questions. Designated women’s
health providers were more comfortable with risk assessment and chemoprevention (P < .046, P < .004) and used risk models more often (P < .045). 63% expressed interest in education about breast cancer prevention.

Conclusions: Breast cancer risk assessment and chemoprevention use by VA primary care is limited by lack of comfort and familiarity. Women‘s health providers are more comfortable and knowledgeable about breast cancer risk models and chemoprevention, offering an opportunity for partnership with high-risk oncologists to improve breast cancer risk assessment and chemoprevention use among female Veterans.

Recommended Reading

Will New American Cancer Society Mammography Policy Change VHA Practice?
AVAHO
Delayed Adjuvant Chemotherapy Significantly Affects Breast Cancer Recovery
AVAHO
USPSTF Supports Mammography Starting at Age 50
AVAHO
False Estradiol Results From Interaction With Fulvestrant
AVAHO
Phone monitoring program helps cut chemotherapy symptom severity
AVAHO
Unraveling the Causes of Breast Cancer Disparities
AVAHO
Protein May Predict Risk for Chemotherapy-Induced Peripheral Neuropathy
AVAHO
Are Breast Cancer Patients Satisfied With Their Care?
AVAHO
Advances in Targeted Therapy for Breast Cancer
AVAHO
Women Living Longer With Metastatic Breast Cancer
AVAHO